BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension

By afschroeder • August 30, 2025

Sahay S, Palevsky H, El-Kersh K, Restrepo-Jaramillo R, Bajwa AA, Desai S, Joly JM, Spikes LA, Eggert MS, Johri S, Shapiro SM, Fisher MR, Shah TG, Ramani GV, Mehta JP, Thrasher CM, Deng C, Smith P, Broderick M, Burger CD. BREEZE Optional Extension Phase: Long-term safety and efficacy of treprostinil dry powder inhaler (Tyvaso DPI) in pulmonary arterial hypertension. Respir Med. 2025 Aug 27;248:108318. doi: 10.1016/j.rmed.2025.108318. Epub ahead of print. PMID: 40882760.

Tags: Cardiology/Epi, Dry powder inhaler, exercise capacity, Prostacyclin dosing, Publications, pulmonary arterial hypertension, Treprostinil, Veterans Administration

Related Posts

Air Pollution Triggers Metabolomic Signature of Mitochondrial Dysfunction in Mice and Humans: Implications for Cardiovascular Disease Development

Lin Y, Qiu X, Gupta R, Ramanathan G, Lu X, Yin F, Fiehn O, Zhang JJ, Kaufman JD, Zhu Y, Rosenfeld M, Araujo JA. Air[...]

Lamin B1 Coordinates the Assembly of the Nuclear Lamina

Kim JR, Kim PH, Tu Y, Carroll J, Koerner JP, Young SG, Fong LG. Lamin B1 Coordinates the Assembly of the Nuclear Lamina. J Cell[...]

Regulators of Mineralization and Long-Term Progression of Aortic Valve and Mitral Annular Calcification: MESA

Bortnick AE, Naveed M, Fu X, Shea K, Kestenbaum B, de Boer I, Ix JH, Kim R, Hamerton E, Kankaria R, Tracy RP, Tsai M,[...]